NSE · ERIS · Pharmaceuticals
Eris Lifesciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹444 Cr with net profit ₹48 Cr — a 10.88% net margin, versus -3.1% the period before.
Shareholding
As of 2026-06-30
- Promoter54.14%
- Public19.4%
- FII5.75%
- DII20.72%
50,798 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.57× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #6 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited(this company) | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
AI analysis
AI-generated · google/gemini-2.5-flashEris Lifesciences Limited has a market capitalization of Rs 20278 Cr. The company reported revenue of Rs 2912 Cr with a profit margin of 19.89%. Its earnings per share (EPS) for the last fiscal year was Rs 45.64. The stock's 52-week high is Rs 1885 and its 52-week low is Rs 1200.
Positives
- +Revenue grew 44% to Rs 2912 Cr in the last fiscal year.
- +The profit margin is 19.89%.
- +Return on Equity (ROE) is 15.87% and Return on Capital Employed (ROCE) is 13.26%.
Negatives
- −Promoters have pledged 16.85% of their total shareholding.
- −Quarterly net profit for December 2025 is Rs 99.72 Cr, which is lower than the Q3 2025 net profit of Rs 120.19 Cr.
- −The trailing twelve months PE ratio is 71.03.
Financial Performance
For the year ending March 2025, Eris Lifesciences reported revenue of Rs 2912 Cr. This represents a revenue growth of 44%. The net profit for the same period was Rs 351.84 Cr, with an EPS of Rs 25.81. The company's EBITDA for March 2025 was Rs 720.1 Cr.
Profitability & Returns
Eris Lifesciences Limited maintains a profit margin of 19.89%. The company's Return on Equity (ROE) stands at 15.87%, and its Return on Capital Employed (ROCE) is 13.26%. For the last fiscal year, EPS was Rs 45.64.
Balance Sheet
The company has a debt-to-equity ratio of 0.97. Its book value per share is Rs 281.62. No additional specific balance sheet figures were provided in the data.
Ownership & Pledges
The public shareholding is 19.40%. A total of 16.85% of promoter shares are pledged. Four promoter entities have pledged shares, including Amit Indubhusan Bakshi (14.01% of his holding), Rajendrakumar Rambhai Patel (31.69% of his holding), Inderjeet Singh Negi (31.69% of his holding), and Kaushal Kamleshkumar Shah (15.66% of his holding).
Data as of — price: 2026-07-30 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.